Supersaturating drug delivery systems: Fast is not necessarily good enough

Journal of Pharmaceutical Sciences

Volumn 101, Issue 1, 2012, Pages 7-9

  Augustijns, Patrick ^a   Brewster, Marcus E ^b  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Dissolution; Precipitation; Solid dosage form; Solubility; Supersaturation

Indexed keywords

ITRACONAZOLE;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; NOTE; THERMODYNAMICS;

EID: 82255162687     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22750     Document Type: Note

References (12)

1. Leuner C, Dressman J. 2000. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 50(1):47-60.
2. Miller DA, DiNunzio JC, Yang W, McGinity JW, Williams RO 3rd. 2008. Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic-to-neutral pH transition. Drug Dev Ind Pharm 34:890-902.
3. Shegokar R, Müller RH. 2010. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 399(1-2):129-139.
4. Gao P, Akrami A, Alvarez F, Hu J, Li L, Ma C, Surapaneni S. 2009. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci 98:516-528.
5. Bak A, Gore A, Yanez E, Stanton M, Tufekcic S, Syed R, Akrami A, Rose M, Surapaneni S, Bostick T, King A, Neervannan S, Ostovic D, Koparkar A. 2008. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci 97:3942-3956.
6. Guzmán HR, Tawa M, Zhang Z, Ratanabanangkoon P, Shaw P, Gardner CR, Chen H, Moreau JP, Almarsson O, Remenar JF. 2007. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci 96:2686-2702.
7. Van Speybroeck M, Barillaro V, Thi TD, Mellaerts R, Martens J, Van Humbeeck J, Vermant J, Annaert P, Van den Mooter G, Augustijns P. 2009. Ordered mesoporous silica material SBA-15: A broad-spectrum formulation platform for poorly soluble drugs. J Pharm Sci 98:2648-2658.
8. Heikkilä T, Salonen J, Tuura J, Kumar N, Salmi T, Murzin DY, Hamdy MS, Mul G, Laitinen L, Kaukonen AM, Hirvonen J, Lehto VP. 2007. Evaluation of mesoporous TCPSi, MCM-41, SBA-15, and TUD-1 materials as API carriers for oral drug delivery. Drug Deliv 14:337-347.
9. Van Speybroeck M, Mols R, Mellaerts R, Thi TD, Martens JA, Van Humbeeck J, Annaert P, Van den Mooter G, Augustijns P. 2010. Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. Eur J Pharm Biopharm 75(3):354-365.
10. Mellaerts R, Aerts CA, Van Humbeeck J, Augustijns P, Van den Mooter G, Martens JA. 2007. Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chem Commun 1375-1377.
11. Van Speybroeck M, Mellaerts R, Mols R, Thi TD, Martens JA, Van Humbeeck J, Annaert P, Van den Mooter G, Augustijns P. 2010. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci 41(5):623-630.
12. Six K, Daems T, de Hoon J, Van Hecken A, Depre M, Bouche MP, Prinsen P, Verreck G, Peeters J, Brewster ME, Van den Mooter G. 2005. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci 24(2-3):179-186.